Cargando…
Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks
It has been demonstrated that patients on hemo- or peritoneal dialysis are particularly susceptible to SARS-CoV-2 infection and impaired seroconversion compared to healthy controls. Follow-up data on vaccination response in dialysis patients is limited but is greatly needed to individualize and guid...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539130/ https://www.ncbi.nlm.nih.gov/pubmed/34696238 http://dx.doi.org/10.3390/vaccines9101130 |
_version_ | 1784588672360775680 |
---|---|
author | Speer, Claudius Schaier, Matthias Nusshag, Christian Töllner, Maximilian Buylaert, Mirabel Kälble, Florian Reichel, Paula Grenz, Julia Süsal, Caner Zeier, Martin Schnitzler, Paul Morath, Christian Klein, Katrin Benning, Louise |
author_facet | Speer, Claudius Schaier, Matthias Nusshag, Christian Töllner, Maximilian Buylaert, Mirabel Kälble, Florian Reichel, Paula Grenz, Julia Süsal, Caner Zeier, Martin Schnitzler, Paul Morath, Christian Klein, Katrin Benning, Louise |
author_sort | Speer, Claudius |
collection | PubMed |
description | It has been demonstrated that patients on hemo- or peritoneal dialysis are particularly susceptible to SARS-CoV-2 infection and impaired seroconversion compared to healthy controls. Follow-up data on vaccination response in dialysis patients is limited but is greatly needed to individualize and guide (booster) vaccination strategies. In this prospective, multicenter study we measured anti-spike S1 and neutralizing antibodies in 124 hemodialysis patients, 41 peritoneal dialysis patients, and 20 age- and sex-matched healthy controls over 12 weeks after homologous BNT162b2 vaccination. Compared to healthy controls, both hemodialysis and peritoneal dialysis patients had lower anti-S1 IgG antibodies (median (IQR) 7.0 (2.8–24.3) and 21.8 (5.8–103.9) versus 134.9 (23.8–283.6), respectively; p < 0.001 and p < 0.05) and a reduced SARS-CoV-2 spike protein–ACE2 binding inhibition caused by vaccine-induced antibodies (median (IQR) 56% (40–81) and 77% (52–89) versus 96% (90–98), respectively; p < 0.001 and p < 0.01) three weeks after the second vaccination. Twelve weeks after the second vaccination, the spike protein–ACE2 binding inhibition significantly decreased to a median (IQR) of 45% (31–60) in hemodialysis patients and 55% (36–78) in peritoneal dialysis patients, respectively (p < 0.001 and p < 0.05). Peritoneal dialysis patients mounted higher antibody levels compared with hemodialysis patients at all time points during the 12-week follow-up. Individual booster vaccinations in high-risk individuals without seroconversion or rapidly waning neutralizing antibody levels are required and further data on the neutralization of emerging variants of concern in these patients are urgently needed. |
format | Online Article Text |
id | pubmed-8539130 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85391302021-10-24 Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks Speer, Claudius Schaier, Matthias Nusshag, Christian Töllner, Maximilian Buylaert, Mirabel Kälble, Florian Reichel, Paula Grenz, Julia Süsal, Caner Zeier, Martin Schnitzler, Paul Morath, Christian Klein, Katrin Benning, Louise Vaccines (Basel) Article It has been demonstrated that patients on hemo- or peritoneal dialysis are particularly susceptible to SARS-CoV-2 infection and impaired seroconversion compared to healthy controls. Follow-up data on vaccination response in dialysis patients is limited but is greatly needed to individualize and guide (booster) vaccination strategies. In this prospective, multicenter study we measured anti-spike S1 and neutralizing antibodies in 124 hemodialysis patients, 41 peritoneal dialysis patients, and 20 age- and sex-matched healthy controls over 12 weeks after homologous BNT162b2 vaccination. Compared to healthy controls, both hemodialysis and peritoneal dialysis patients had lower anti-S1 IgG antibodies (median (IQR) 7.0 (2.8–24.3) and 21.8 (5.8–103.9) versus 134.9 (23.8–283.6), respectively; p < 0.001 and p < 0.05) and a reduced SARS-CoV-2 spike protein–ACE2 binding inhibition caused by vaccine-induced antibodies (median (IQR) 56% (40–81) and 77% (52–89) versus 96% (90–98), respectively; p < 0.001 and p < 0.01) three weeks after the second vaccination. Twelve weeks after the second vaccination, the spike protein–ACE2 binding inhibition significantly decreased to a median (IQR) of 45% (31–60) in hemodialysis patients and 55% (36–78) in peritoneal dialysis patients, respectively (p < 0.001 and p < 0.05). Peritoneal dialysis patients mounted higher antibody levels compared with hemodialysis patients at all time points during the 12-week follow-up. Individual booster vaccinations in high-risk individuals without seroconversion or rapidly waning neutralizing antibody levels are required and further data on the neutralization of emerging variants of concern in these patients are urgently needed. MDPI 2021-10-04 /pmc/articles/PMC8539130/ /pubmed/34696238 http://dx.doi.org/10.3390/vaccines9101130 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Speer, Claudius Schaier, Matthias Nusshag, Christian Töllner, Maximilian Buylaert, Mirabel Kälble, Florian Reichel, Paula Grenz, Julia Süsal, Caner Zeier, Martin Schnitzler, Paul Morath, Christian Klein, Katrin Benning, Louise Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks |
title | Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks |
title_full | Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks |
title_fullStr | Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks |
title_full_unstemmed | Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks |
title_short | Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks |
title_sort | longitudinal humoral responses after covid-19 vaccination in peritoneal and hemodialysis patients over twelve weeks |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539130/ https://www.ncbi.nlm.nih.gov/pubmed/34696238 http://dx.doi.org/10.3390/vaccines9101130 |
work_keys_str_mv | AT speerclaudius longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks AT schaiermatthias longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks AT nusshagchristian longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks AT tollnermaximilian longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks AT buylaertmirabel longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks AT kalbleflorian longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks AT reichelpaula longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks AT grenzjulia longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks AT susalcaner longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks AT zeiermartin longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks AT schnitzlerpaul longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks AT morathchristian longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks AT kleinkatrin longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks AT benninglouise longitudinalhumoralresponsesaftercovid19vaccinationinperitonealandhemodialysispatientsovertwelveweeks |